Analysis of the Progression of Cervical Cancer in a Low-and-middle-income Country: From Pre-malignancy to Invasive Disease

Overview

Journal Tumour Virus Res

Specialties Microbiology
Oncology

Date 2024 Dec 13

PMID 39672307

Authors

Emma Robinson

Isabel Rodriguez

Victor Argueta

Yi Xie

Hong Lou

Rose Milano

Hyo Jung Lee

Laurie Burdett

Sambit K Mishra

Meredith Yeager

Lisa Mirabello

Michael Dean

Roberto Orozco

Affiliations

Soon will be listed here.

Abstract

To better understand cervical cancer progression, we analyzed RNA from 262 biopsies from women referred for colposcopy. We determined the HPV type and analyzed the expression of 51 genes. HPV31 was significantly more prevalent in precancer than stage 1 cancer and invasive cancer (p < 0.0001), and HPV16 increased in invasive disease (p < 0.0001). CCNE1, MELTF, and ULBP2 were significantly increased in HPV16-positive compared to HPV31 precancers, while NECTIN2 and HLA-E expression decreased. Markers of the innate immune system, DNA repair genes, and cell cycle genes are significantly increased during cancer progression (p = 0.0001). In contrast, the TP53 and RB1 tumor suppressor gene expression is significantly decreased in cancer cells. The T cell markers CD28 and FLT3LG expression decreased in cancer while FOXP3, IDO1, and ULBP2 expression increased. There is a significantly higher survival rate in individuals with increased expression of CD28 (p = 0.0005), FOXP3 (p = 0.0002), IDO1 (p = 0.038), FLT3LG (p = 0.026), APOBEC3B (p = 0.0011), and RUNX3 (p = 0.019), and a significantly lower survival rate in individuals with increased expression of ULBP2 (p = 0.035). These results will help us elucidate the molecular factors influencing the progression of cervical precancer to cancer. Understanding the risk of progression of specific HPV types and sublineages may aid in the triage of positive patients, and better knowledge of the immune response may aid in developing and applying immunotherapies.

References

Olesen T, Sand F, Rasmussen C, Albieri V, Toft B, Norrild B . Prevalence of human papillomavirus DNA and p16 in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2018; 20(1):145-158. DOI: 10.1016/S1470-2045(18)30682-X. View

Pinheiro M, Harari A, Schiffman M, Clifford G, Chen Z, Yeager M . Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses. 2021; 13(10). PMC: 8540939. DOI: 10.3390/v13101948. View

Litwin T, Irvin S, Chornock R, Sahasrabuddhe V, Stanley M, Wentzensen N . Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. Br J Cancer. 2020; 124(4):831-841. PMC: 7884592. DOI: 10.1038/s41416-020-01184-x. View

Cullen M, Boland J, Schiffman M, Zhang X, Wentzensen N, Yang Q . Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. Papillomavirus Res. 2015; 1:3-11. PMC: 4669577. DOI: 10.1016/j.pvr.2015.05.004. View

Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B . Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2022; 11(2):e197-e206. PMC: 9848409. DOI: 10.1016/S2214-109X(22)00501-0. View

Yang S, Liu Y, Li M, Ng C, Yang S, Wang S . FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017; 16(1):124. PMC: 5514503. DOI: 10.1186/s12943-017-0700-1. View

Ji L, Zhao G, Zhang P, Huo W, Dong P, Watari H . Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells. J Cancer. 2018; 9(24):4578-4585. PMC: 6299381. DOI: 10.7150/jca.28040. View

Rodriguez A, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle P . Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008; 100(7):513-7. PMC: 3705579. DOI: 10.1093/jnci/djn044. View

Waldhauer I, Steinle A . Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006; 66(5):2520-6. DOI: 10.1158/0008-5472.CAN-05-2520. View

10.

Lou H, Villagran G, Boland J, Im K, Polo S, Zhou W . Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res. 2015; 21(23):5360-70. PMC: 4668220. DOI: 10.1158/1078-0432.CCR-14-1837. View

11.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

12.

Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, Coutlee F . p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol. 2011; 86(1):94-107. PMC: 3255875. DOI: 10.1128/JVI.00751-11. View

13.

Hoffmann I, Dragomir M, Monje N, Keunecke C, Kunze C, Schallenberg S . Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer. Neoplasia. 2023; 44:100934. PMC: 10502412. DOI: 10.1016/j.neo.2023.100934. View

14.

Cueto F, Sancho D . The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy. Cancers (Basel). 2021; 13(7). PMC: 8037622. DOI: 10.3390/cancers13071525. View

15.

Nagarsheth N, Norberg S, Sinkoe A, Adhikary S, Meyer T, Lack J . TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021; 27(3):419-425. PMC: 9620481. DOI: 10.1038/s41591-020-01225-1. View

16.

Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T . FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2014; 1(4):625-632. PMC: 3915667. DOI: 10.3892/mco.2013.107. View

17.

Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett T, Cheung L, Chen X . A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020; 22:100293. PMC: 7264956. DOI: 10.1016/j.eclinm.2020.100293. View

18.

Pallotta M, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A . Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. FEBS J. 2021; 289(20):6099-6118. PMC: 9786828. DOI: 10.1111/febs.16086. View

19.

Zhang L, Shi L . The E2F1/MELTF axis fosters the progression of lung adenocarcinoma by regulating the Notch signaling pathway. Mutat Res. 2023; 827:111837. DOI: 10.1016/j.mrfmmm.2023.111837. View

20.

Liu W, Quan B, Li M, Zhang F, Hu K, Yin X . PVR-A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. Diagnostics (Basel). 2022; 12(12). PMC: 9777148. DOI: 10.3390/diagnostics12122953. View